RHOA and cancer: Ohtsuka et al. showed that LRRFIP1/GCF2 bound to Dsv, which is a mediator for both the Wnt/canonical and Wnt/ noncanonical pathways, and that siRNA knockdown of LRRFIP1/GCF2 inhibited the activation of RhoA by Wnt treatment in human cancer cell lines.